ADC Therapeutics outlines $600M–$1B peak revenue target for ZYNLONTA as LOTIS-5 and LOTIS-7 advance (NYSE:ADCT)

Core Insights - ADC Therapeutics has set a peak revenue target for ZYNLONTA between $600 million and $1 billion as it advances clinical trials LOTIS-5 and LOTIS-7 [2] Management Strategy - CEO Ameet Mallik emphasized a strategic focus on ZYNLONTA, which includes optimized life cycle management and the advancement of clinical trials [2] - The company aims to reduce operating costs by concentrating its efforts on ZYNLONTA and related trials [2]